Format

Send to

Choose Destination
Cancer Invest. 2018;36(6):356-361. doi: 10.1080/07357907.2018.1499028. Epub 2018 Aug 10.

Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer.

Author information

1
a Departments of Medicine, Oncology Division , Washington University in St Louis , St Louis , Missouri , USA.
2
b Departments of Oncology , The Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
3
c St. Mary's Hospital , Richmond , Virginia , USA.

Abstract

BACKGROUND:

Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer.

METHODS:

Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital.

RESULTS:

Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation.

CONCLUSION:

Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL's relationship to survival.

KEYWORDS:

Lymphopenia; Radiation; Rectal cancer

PMID:
30095290
DOI:
10.1080/07357907.2018.1499028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center